Physician profile
Levent Akduman
NPI 1245344605
$46,795.09
in general payments reported to CMS, 2019-2025
25 companies · $15K in 2025
The $15K reported for 2025 was more than what 96% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,840 · 2020: $1,135 · 2021: $1,508 · 2022: $803 · 2023: $5,913 · 2024: $14K · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $22K · Food and Beverage: $6,709 · Consulting Fee: $3,000 · Honoraria: $2,550.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $22,250.00 |
| Food and Beverage | $6,708.70 |
| Consulting Fee | $3,000.00 |
| Honoraria | $2,550.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $23,396.37 | 2022-2025 | Ozurdex, Durysta, Lumigan |
| Allergan, INC. | $9,322.10 | 2019-2021 | |
| Astellas Pharma US INC | $3,590.07 | 2023-2025 | Izervay |
| Ani Pharmaceuticals, INC. | $2,876.78 | 2025 | Yutiq, Iluvien, Purified Cortrophin Gel |
| Alimera Sciences, INC. | $1,075.05 | 2019-2024 | Iluvien, Yutiq |
| Alcon Vision LLC | $1,000.15 | 2020-2025 | Unity, Clareon, Acrysof Iq Vivity |
| Genentech USA, INC. | $934.72 | 2019-2025 | Vabysmo, Susvimo |
| Regeneron Healthcare Solutions, INC. | $688.63 | 2019-2025 | Eylea Hd, Eylea |
| Novartis Pharmaceuticals Corporation | $561.23 | 2019 | |
| Apellis Pharmaceuticals, INC. | $425.74 | 2023-2025 | Syfovre |
| Mallinckrodt Hospital Products INC. | $413.58 | 2020-2024 | Acthar |
| Bausch & Lomb Americas INC. | $406.40 | 2022-2025 | Miebo, Xiidra, Stellaris |
| Biotissue Holdings INC. | $319.92 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $310.24 | 2022 | |
| Biogen, INC. | $265.42 | 2022-2023 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $256.72 | 2019-2021 | |
| Eyevance Pharmaceuticals LLC | $223.82 | 2020-2022 | |
| Sun Pharmaceutical Industries INC. | $179.84 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $139.19 | 2019 | |
| Aerie Pharmaceuticals, INC. | $122.77 | 2019 | |
| Eyepoint US, INC. | $102.69 | 2023 | |
| Harrow Eye, LLC | $64.80 | 2025 | Triesence |
| Sandoz INC. | $63.37 | 2024 | Cimerli |
| Dutch Ophthalmic, USA | $41.17 | 2023 | Eva, Combined Machine, Tissueblue |
| Merck Sharp & Dohme LLC | $14.32 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Levent Akduman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.